The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Golovina V.I.

Pirogov Russian National Research Medical University

Seliverstov E.I.

Pirogov Russian National Research Medical University

Efremova O.I.

Pirogov Russian National Research Medical University

Zolotukhin I.A.

Pirogov Russian National Research Medical University

Cytokines in Pathogenesis of Varicose Veins

Authors:

Golovina V.I., Seliverstov E.I., Efremova O.I., Zolotukhin I.A.

More about the authors

Journal: Journal of Venous Disorders. 2021;15(2): 117‑126

DOI: 10.17116/flebo202115021117

Views: 1732

Downloaded: 106

Download PDF (RU)
Contact the author
Table of contents

CYTOKINES IN PATHOGENESIS OF VARICOSE VEINS
CYTOKINES IN PATHOGENESIS OF VARICOSE VEINS

To cite this article:

Golovina VI, Seliverstov EI, Efremova OI, Zolotukhin IA. Cytokines in Pathogenesis of Varicose Veins. Journal of Venous Disorders. 2021;15(2):117‑126. (In Russ.)
https://doi.org/10.17116/flebo202115021117

Подписка 2025-2 (Journal of Venous Disorders)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Endo­venous Laser Abla­tion with Wave­lengths 1940 and 1560 nm. Journal of Venous Diso­rders. 2024;(2):82-88
Impact of Micronized Puri­fied Flavonoid Fraction on Venous Symptoms After Endo­venous Laser Abla­tion: a Randomized Controlled Trial DEMO. Journal of Venous Diso­rders. 2024;(2):122-131
Arti­ficial Inte­lligence Based Application Accu­racy in Diagnostics of C1-C2 Chro­nic Venous Disease. Journal of Venous Diso­rders. 2024;(2):132-138
Effect of 18—21 mm Hg Compression Knee Socks on Venous Symptoms in Patients with Chro­nic Venous Disease: a Randomized Controlled Trial GOLIATH. Journal of Venous Diso­rders. 2024;(2):139-152
Endo­venous Laser Abla­tion with Wave­lengths 1940 and 1560 nm. Journal of Venous Diso­rders. 2024;(2):82-88
Impact of Micronized Puri­fied Flavonoid Fraction on Venous Symptoms After Endo­venous Laser Abla­tion: a Randomized Controlled Trial DEMO. Journal of Venous Diso­rders. 2024;(2):122-131
Arti­ficial Inte­lligence Based Application Accu­racy in Diagnostics of C1-C2 Chro­nic Venous Disease. Journal of Venous Diso­rders. 2024;(2):132-138
Effect of 18—21 mm Hg Compression Knee Socks on Venous Symptoms in Patients with Chro­nic Venous Disease: a Randomized Controlled Trial GOLIATH. Journal of Venous Diso­rders. 2024;(2):139-152
Cognitive impairment in multiple system atro­phy — exclusion criteria or an inte­gral part of the clinical picture?. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4-2):86-91
Inte­rleukin-6 as a marker of infe­ction gene­ralization in neonatal sepsis. Russian Journal of Anesthesiology and Reanimatology. 2024;(3):35-42

Exact mechanisms of varicose veins are still unclear and actively studied by clinicians and scientists. Vein wall transformation is a result of remodeling processes that are triggered by the so-called vein-specific inflammation. This chronic process involves a complex of interactions between the cells responsible for inflammatory response (neutrophils, lymphocytes, monocytes, macrophages), endothelial cells, vascular smooth muscle cells and extracellular matrix. In addition, vein-specific inflammation occurs with active participation of cytokines. These are a diverse group of small proteins released by different immune and vascular cells in picomolar and nanomolar concentrations. Cytokines activate specific receptors and modulate the functions of various cells and tissues. The role of cytokines in pathogenesis of varicose veins remains poorly understood due to difficult research of their mechanism of action. It is assumed that their activity mediates impaired regulation of degradation processes in extracellular matrix, modification of the components of extracellular matrix (collagen and elastin) and decrease in the number of smooth muscle cells. All these processes reduce an efficiency of vascular wall contraction due to fragmentation of the muscle layer. Cytokines are also involved in activation of leukocytes that results a release of free radicals, activation of proteases and subsequent degradation of smooth muscle cells. In this review, we analyzed various data on cytokines and studies devoted to possible impact of various molecules on development of primary varicose veins.

Keywords:

varicose veins
mechanism
vein-specific inflammation
cytokines
venoactive drugs

Authors:

Golovina V.I.

Pirogov Russian National Research Medical University

Seliverstov E.I.

Pirogov Russian National Research Medical University

Efremova O.I.

Pirogov Russian National Research Medical University

Zolotukhin I.A.

Pirogov Russian National Research Medical University

Received:

29.03.2021

Accepted:

12.04.2021

List of references:

  1. Raffetto JD, Khalil RA. Mechanisms of varicose vein formation: valve dysfunction and wall dilation. Phlebology. 2008;23(2):85-98.  https://doi.org/10.1258/phleb.2007.007027
  2. Zolotukhin IA, Seliverstov EI, Shevtsov YN, Avakiants IP, Nikishkov AS, Tatarintsev AM, Kirienko AI. Prevalence and Risk Factors for Chronic Venous Disease in the General Russian Population. Eur J Vasc Endovasc Surg. 2017;54(6):752-758.  https://doi.org/10.1016/j.ejvs.2017.08.033
  3. Aguilar-Ferrándiz ME, Castro-Sánchez AM, Matarán-Peñarrocha GA, de Dios Luna J, Moreno-Lorenzo C, Del Pozo E. Evaluation of pain associated with chronic venous insufficiency in Spanish postmenopausal women. Menopause. 2015;22(1):88-95.  https://doi.org/10.1097/GME.0000000000000277
  4. Dzieciuchowicz Ł, Krasiński Z, Motowidlo K, Gabriel M. The aetiology and influence of age and gender on the development of advanced chronic venous insufficiency in the population of patients of semi-urban county outpatient vascular clinic in Poland. Phlebology. 2011;26(2):56-61.  https://doi.org/10.1258/phleb.2010.009079
  5. Bergan JJ, Schmid-Schönbein GW, Smith PD, Nicolaides AN, Boisseau MR, Eklof B. Chronic venous disease. N Engl J Med. 2006;355(5):488-498.  https://doi.org/10.1056/NEJMra055289
  6. Iannuzzi A, Panico S, Ciardullo AV, Bellati C, Cioffi V, Iannuzzo G, Celentano E, Berrino F, Rubba P. Varicose veins of the lower limbs and venous capacitance in postmenopausal women: relationship with obesity. J Vasc Surg. 2002;36(5):965-968.  https://doi.org/10.1067/mva.2002.128315
  7. Mazaishvili KV, Chen VI. Chroic venous diseases of lower limbs in Petropavlovsk-Kamchatsky. Flebologiya. 2008;2(4):52-54. (In Russ.).
  8. Perrin M, Eklof B, VAN Rij A, Labropoulos N, Vasquez M, Nicolaides A, Blattler W, Bouhassira D, Bouskela E, Carpentier P, Darvall K, DE Maeseneer M, Flour M, Guex JJ, Hamel-Desnos C, Kakkos S, Launois R, Lugli M, Maleti O, Mansilha A, NEGLéN P, Rabe E, Shaydakov E. Venous symptoms: the SYM Vein Consensus statement developed under the auspices of the European Venous Forum. Int Angiol. 2016;35(4):374-398. 
  9. Trendelenburg F. Ueber die unterbindung der vena saphena magna bei unterschenkelvaricen. Beitr Z Klin Chir. 1891;7:195-210. 
  10. Meissner MH, Gloviczki P, Bergan J, Kistner RL, Morrison N, Pannier F, Pappas PJ, Rabe E, Raju S, Villavicencio JL. Primary chronic venous disorders. J Vasc Surg. 2007;46(suppl S):54-67.  https://doi.org/10.1016/j.jvs.2007.08.038
  11. Alexander CJ. The theoretical basis of varicose vein formation. Med J Aust. 1972;1(6):258-261.  https://doi.org/10.5694/j.1326-5377.1972.tb50912.x
  12. Cotton LT. Varicose veins. Gross anatomy and development. Br J Surg. 1961;48:589-598.  https://doi.org/10.1002/bjs.18004821203
  13. Labropoulos N, Giannoukas AD, Delis K, Mansour MA, Kang SS, Nicolaides AN, Lumley J, Baker WH. Where does venous reflux start? J Vasc Surg. 1997;26(5):736-742.  https://doi.org/10.1016/s0741-5214(97)70084-3
  14. Clarke GH, Vasdekis SN, Hobbs JT, Nicolaides AN. Venous wall function in the pathogenesis of varicose veins. Surgery. 1992;111(4):402-408. 
  15. Leu HJ, Vogt M, Pfrunder H. Morphological alterations of non-varicose and varicose veins. (A morphological contribution to the discussion on pathogenesis of varicose veins). Basic Res Cardiol. 1979;74(4):435-444.  https://doi.org/10.1007/BF01908395
  16. Vanhoutte PM, Corcaud S, de Montrion C. Venous disease: from pathophysiology to quality of life. Angiology. 1997;48(7):559-567.  https://doi.org/10.1177/000331979704800702
  17. Woodside KJ, Hu M, Burke A, Murakami M, Pounds LL, Killewich LA, Daller JA, Hunter GC. Morphologic characteristics of varicose veins: possible role of metalloproteinases. J Vasc Surg. 2003;38(1):162-169.  https://doi.org/10.1016/s0741-5214(03)00134-4
  18. Badier-Commander C, Verbeuren T, Lebard C, Michel JB, Jacob MP. Increased TIMP/MMP ratio in varicose veins: a possible explanation for extracellular matrix accumulation. J Pathol. 2000;192(1):105-112. 
  19. Kockx MM, Knaapen MW, Bortier HE, Cromheeke KM, Boutherin-Falson O, Finet M. Vascular remodeling in varicose veins. Angiology. 1998;49(11):871-877.  https://doi.org/10.1177/000331979804901101
  20. Sansilvestri-Morel P, Nonotte I, Fournet-Bourguignon MP, Rupin A, Fabiani JN, Verbeuren TJ, Vanhoutte PM. Abnormal deposition of extracellular matrix proteins by cultured smooth muscle cells from human varicose veins. J Vasc Res. 1998;35(2):115-123.  https://doi.org/10.1159/000025573
  21. Travers JP, Brookes CE, Evans J, Baker DM, Kent C, Makin GS, Mayhew TM. Assessment of wall structure and composition of varicose veins with reference to collagen, elastin and smooth muscle content. Eur J Vasc Endovasc Surg. 1996;11(2):230-237.  https://doi.org/10.1016/s1078-5884(96)80058-x
  22. Gillespie DL, Patel A, Fileta B, Chang A, Barnes S, Flagg A, Kidwell M, Villavicencio JL, Rich NM. Varicose veins possess greater quantities of MMP-1 than normal veins and demonstrate regional variation in MMP-1 and MMP-13. J Surg Res. 2002;106(2):233-238.  https://doi.org/10.1006/jsre.2002.6455
  23. Venturi M, Bonavina L, Annoni F, Colombo L, Butera C, Peracchia A, Mussini E. Biochemical assay of collagen and elastin in the normal and varicose vein wall. J Surg Res. 1996;60(1):245-248.  https://doi.org/10.1006/jsre.1996.0038
  24. Eklöf B, Rutherford RB, Bergan JJ, Carpentier PH, Gloviczki P, Kistner RL, Meissner MH, Moneta GL, Myers K, Padberg FT, Perrin M, Ruckley CV, Smith PC, Wakefield TW; American Venous Forum International Ad Hoc Committee for Revision of the CEAP Classification. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg. 2004;40(6):1248-1252. https://doi.org/10.1016/j.jvs.2004.09.027
  25. Gandhi RH, Irizarry E, Nackman GB, Halpern VJ, Mulcare RJ, Tilson MD. Analysis of the connective tissue matrix and proteolytic activity of primary varicose veins. J Vasc Surg. 1993;18(5):814-820. 
  26. Bergan JJ, Pascarella L, Schmid-Schönbein GW. Pathogenesis of primary chronic venous disease: Insights from animal models of venous hypertension. J Vasc Surg. 2008;47(1):183-192.  https://doi.org/10.1016/j.jvs.2007.09.028
  27. Michiels C, Arnould T, Thibaut-Vercruyssen R, Bouaziz N, Janssens D, Remacle J. Perfused human saphenous veins for the study of the origin of varicose veins: role of the endothelium and of hypoxia. Int Angiol. 1997;16(2):134-141. 
  28. Hirano T. Molecular basis underlying functional pleiotropy of cytokines and growth factors. Biochem Biophys Res Commun. 1999;260(2):303-308.  https://doi.org/10.1006/bbrc.1999.0609
  29. Ozaki K, Leonard WJ. Cytokine and cytokine receptor pleiotropy and redundancy. J Biol Chem. 2002;277(33):29355-29358. https://doi.org/10.1074/jbc.R200003200
  30. Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol. 2009;78(6):539-552.  https://doi.org/10.1016/j.bcp.2009.04.029
  31. Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003; 3(1):23-35.  https://doi.org/10.1038/nri978
  32. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86(2):515-581.  https://doi.org/10.1152/physrev.00024.2005
  33. McNicol A, Israels SJ. Beyond hemostasis: the role of platelets in inflammation, malignancy and infection. Cardiovasc Hematol Disord Drug Targets. 2008;8(2):99-117.  https://doi.org/10.2174/187152908784533739
  34. Satokowa H, Hoshino S, Igari T, Iwaya F, Midorikawa H. The appearance of cytokines and adhesion molecules in saphenous vein valves in chronic venous insufficiency. Phlebology. 2002;16(3):106-110.  https://doi.org/10.1177/026835550201600305
  35. Takase S, Bergan JJ, Schmid-Schönbein G. Expression of adhesion molecules and cytokines on saphenous veins in chronic venous insufficiency. Ann Vasc Surg. 2000;14(5):427-435.  https://doi.org/10.1007/s100169910092
  36. Oklü R, Hesketh R. The latent transforming growth factor beta binding protein (LTBP) family. Biochem J. 2000;352(Pt 3):601-610. 
  37. Pascual G, Mendieta C, García-Honduvilla N, Corrales C, Bellón JM, Buján J. TGF-beta1 upregulation in the aging varicose vein. J Vasc Res. 2007;44(3):192-201.  https://doi.org/10.1159/000100375
  38. Oklu R, Habito R, Mayr M, Deipolyi AR, Albadawi H, Hesketh R, Walker TG, Linskey KR, Long CA, Wicky S, Stoughton J, Watkins MT. Pathogenesis of varicose veins. J Vasc Interv Radiol. 2012;23(1):33-39.  https://doi.org/10.1016/j.jvir.2011.09.010
  39. Oklü R, Hesketh TR, Metcalfe JC, Kemp PR. Expression of alternatively spliced human latent transforming growth factor beta binding protein-1. FEBS Lett. 1998;435(2-3):143-148.  https://doi.org/10.1016/s0014-5793(98)01054-0
  40. Oklü R, Metcalfe JC, Hesketh TR, Kemp PR. Loss of a consensus heparin binding site by alternative splicing of latent transforming growth factor-beta binding protein-1. FEBS Lett. 1998;425(2):281-285.  https://doi.org/10.1016/s0014-5793(98)00257-9
  41. Kanzaki T, Olofsson A, Morén A, Wernstedt C, Hellman U, Miyazono K, Claesson-Welsh L, Heldin CH. TGF-beta 1 binding protein: a component of the large latent complex of TGF-beta 1 with multiple repeat sequences. Cell. 1990;61(6):1051-1061. https://doi.org/10.1016/0092-8674(90)90069-q
  42. Taipale J, Lohi J, Saarinen J, Kovanen PT, Keski-Oja J. Human mast cell chymase and leukocyte elastase release latent transforming growth factor-beta 1 from the extracellular matrix of cultured human epithelial and endothelial cells. J Biol Chem. 1995;270(9):4689-4696. https://doi.org/10.1074/jbc.270.9.4689
  43. Sayer GL, Smith PD. Immunocytochemical characterisation of the inflammatory cell infiltrate of varicose veins. Eur J Vasc Endovasc Surg. 2004; 28(5):479-483.  https://doi.org/10.1016/j.ejvs.2004.07.023
  44. Yamada T, Tomita S, Mori M, Sasatomi E, Suenaga E, Itoh T. Increased mast cell infiltration in varicose veins of the lower limbs: a possible role in the development of varices. Surgery. 1996;119(5):494-497.  https://doi.org/10.1016/s0039-6060(96)80256-x
  45. Lal BK, Saito S, Pappas PJ, Padberg FT Jr, Cerveira JJ, Hobson RW 2nd, Durán WN. Altered proliferative responses of dermal fibroblasts to TGF-beta1 may contribute to chronic venous stasis ulcer. J Vasc Surg. 2003;37(6): 1285-1293. https://doi.org/10.1016/s0741-5214(02)75295-6
  46. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol. 1999;277(1):1-9.  https://doi.org/10.1152/ajpcell.1999.277.1.C1
  47. Pappas PJ, Lal BK, Ohara N, Saito S, Zapiach L, Durán WN. Regulation of matrix contraction in chronic venous disease. Eur J Vasc Endovasc Surg. 2009;38(4):518-529.  https://doi.org/10.1016/j.ejvs.2009.05.012
  48. Saito S, Trovato MJ, You R, Lal BK, Fasehun F, Padberg FT Jr, Hobson RW 2nd, Durán WN, Pappas PJ. Role of matrix metalloproteinases 1, 2, and 9 and tissue inhibitor of matrix metalloproteinase-1 in chronic venous insufficiency. J Vasc Surg. 2001;34(5):930-938.  https://doi.org/10.1067/mva.2001.119503
  49. Lim CS, Shalhoub J, Gohel MS, Shepherd AC, Davies AH. Matrix metalloproteinases in vascular disease--a potential therapeutic target? Curr Vasc Pharmacol. 2010;8(1):75-85.  https://doi.org/10.2174/157016110790226697
  50. Buján J, Gimeno MJ, Jiménez JA, Kielty CM, Mecham RP, Bellón JM. Expression of elastic components in healthy and varicose veins. World J Surg. 2003;27(8):901-905.  https://doi.org/10.1007/s00268-003-6897-8
  51. Jacob T, Hingorani A, Ascher E. Overexpression of transforming growth factor-beta1 correlates with increased synthesis of nitric oxide synthase in varicose veins. J Vasc Surg. 2005;41(3):523-530.  https://doi.org/10.1016/j.jvs.2004.12.044
  52. Kowalewski R, Malkowski A, Sobolewski K, Gacko M. Evaluation of transforming growth factor-beta signaling pathway in the wall of normal and varicose veins. Pathobiology. 2010;77(1):1-6.  https://doi.org/10.1159/000272948
  53. Oklu R, Walker TG, Wicky S, Hesketh R. Angiogenesis and current antiangiogenic strategies for the treatment of cancer. J Vasc Interv Radiol. 2010;21(12):1791-1805. https://doi.org/10.1016/j.jvir.2010.08.009
  54. McCollum PT, Bush JA, James G, Mason T, O’Kane S, McCollum C, Krievins D, Shiralkar S, Ferguson MW. Randomized phase II clinical trial of avotermin versus placebo for scar improvement. Br J Surg. 2011;98(7):925-934.  https://doi.org/10.1002/bjs.7438
  55. Satokawa H, Hoshino S, Igari T, Iwaya F, Midorikawa H. The Appearance of Cytokines and Adhesion Molecules in Saphenous Vein Valves in Chronic Venous Insufficiency. Phlebology. 2002;16(3):106-110.  https://doi.org/10.1177/026835550201600305
  56. Lattimer CR, Kalodiki E, Geroulakos G, Hoppensteadt D, Fareed J. Are Inflammatory Biomarkers Increased in Varicose Vein Blood? Clin Appl Thromb Hemost. 2016;22(7):656-664.  https://doi.org/10.1177/1076029616645330
  57. Eschrich J, Meyer R, Kuk H, Wagner AH, Noppeney T, Debus S, Hecker M, Korff T. Varicose remodeling of veins is suppressed by 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. J Am Heart Assoc. 2016;5(2):e002405. https://doi.org/10.1161/JAHA.115.002405
  58. Shadrina AS, Smetanina MA, Sevost’ianova KS, Seliverstov EI, Ilyukhin EA, Voronina EN, Zolotukhin IA, Filipenko ML. Functional polymorphism rs1024611 in the MCP1 gene is associated with the risk of varicose veins of lower extremities. J Vasc Surg Venous Lymphat Disord. 2017;5(4):561-566.  https://doi.org/10.1016/j.jvsv.2016.12.008
  59. Solá Ldel R, Aceves M, Dueñas AI, González-Fajardo JA, Vaquero C, Crespo MS, García-Rodríguez C. Varicose veins show enhanced chemokine expression. Eur J Vasc Endovasc Surg. 2009;38(5):635-641.  https://doi.org/10.1016/j.ejvs.2009.07.021
  60. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AM. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA. 1990;87(13): 5134-5138. https://doi.org/10.1073/pnas.87.13.5134
  61. Standiford TJ, Kunkel SL, Phan SH, Rollins BJ, Strieter RM. Alveolar macrophage-derived cytokines induce monocyte chemoattractant protein-1 expression from human pulmonary type II-like epithelial cells. J Biol Chem. 1991;266(15):9912-9918.
  62. Brown Z, Strieter RM, Neild GH, Thompson RC, Kunkel SL, Westwick J. IL-1 receptor antagonist inhibits monocyte chemotactic peptide 1 generation by human mesangial cells. Kidney Int. 1992;42(1):95-101.  https://doi.org/10.1038/ki.1992.266
  63. Barna BP, Pettay J, Barnett GH, Zhou P, Iwasaki K, Estes ML. Regulation of monocyte chemoattractant protein-1 expression in adult human non-neoplastic astrocytes is sensitive to tumor necrosis factor (TNF) or antibody to the 55-kDa TNF receptor. J Neuroimmunol. 1994;50(1):101-107.  https://doi.org/10.1016/0165-5728(94)90220-8
  64. Fuentes ME, Durham SK, Swerdel MR, Lewin AC, Barton DS, Megill JR, Bravo R, Lira SA. Controlled recruitment of monocytes and macrophages to specific organs through transgenic expression of monocyte chemoattractant protein-1. J Immunol. 1995;155(12):5769-5776.
  65. Viedt C, Vogel J, Athanasiou T, Shen W, Orth SR, Kübler W, Kreuzer J. Monocyte chemoattractant protein-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-kappaB and activator protein-1. Arterioscler Thromb Vasc Biol. 2002;22(6):914-920.  https://doi.org/10.1161/01.atv.0000019009.73586.7f
  66. Yoshimura T, Robinson EA, Tanaka S, Appella E, Leonard EJ. Purification and amino acid analysis of two human monocyte chemoattractants produced by phytohemagglutinin-stimulated human blood mononuclear leukocytes. J Immunol. 1989;142(6):1956-1962.
  67. Yoshimura T, Yuhki N, Moore SK, Appella E, Lerman MI, Leonard EJ. Human monocyte chemoattractant protein-1 (MCP-1). Full-length cDNA cloning, expression in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE. FEBS Lett. 1989;244(2):487-493.  https://doi.org/10.1016/0014-5793(89)80590-3
  68. Sørensen TL, Ransohoff RM, Strieter RM, Sellebjerg F. Chemokine CCL2 and chemokine receptor CCR2 in early active multiple sclerosis. Eur J Neurol. 2004;11(7):445-449.  https://doi.org/10.1111/j.1468-1331.2004.00796.x
  69. Hayashida K, Nanki T, Girschick H, Yavuz S, Ochi T, Lipsky PE. Synovial stromal cells from rheumatoid arthritis patients attract monocytes by producing MCP-1 and IL-8. Arthritis Res. 2001;3(2):118-126.  https://doi.org/10.1186/ar149
  70. Kusano KF, Nakamura K, Kusano H, Nishii N, Banba K, Ikeda T, Hashimoto K, Yamamoto M, Fujio H, Miura A, Ohta K, Morita H, Saito H, Emori T, Nakamura Y, Kusano I, Ohe T. Significance of the level of monocyte chemoattractant protein-1 in human atherosclerosis. Circ J. 2004;68(7):671-676.  https://doi.org/10.1253/circj.68.671
  71. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA. 2003;100(12):7265-7270. https://doi.org/10.1073/pnas.1133870100
  72. Del Río L, Caballero L, González-Fajardo JA, Martín M, Torres A, San José I. Factores pronósticos e influencia de la terapia con antiinflamatorios no esteroideos en la insuficiencia venosa crónica (IVC) grado IV. Angiología. 2002;54:241. 
  73. Schmid-Schönbein GW, Takase S, Bergan JJ. New advances in the understanding of the pathophysiology of chronic venous insufficiency. Angiology. 2001;52(suppl 1):27-34.  https://doi.org/10.1177/0003319701052001S04
  74. Aceves M, Dueñas A, Gómez C, San Vicente E, Crespo MS, García-Rodríguez C. A new pharmacological effect of salicylates: inhibition of NFAT-dependent transcription. J Immunol. 2004;173(9):5721-5729. https://doi.org/10.4049/jimmunol.173.9.5721
  75. Dichtl W, Nilsson L, Goncalves I, Ares MP, Banfi C, Calara F, Hamsten A, Eriksson P, Nilsson J. Very low-density lipoprotein activates nuclear factor-kappaB in endothelial cells. Circ Res. 1999;84(9):1085-1094. https://doi.org/10.1161/01.res.84.9.1085
  76. Guijarro C, Kim Y, Schoonover CM, Massy ZA, O’Donnell MP, Kasiske BL, Keane WF, Kashtan CE. Lovastatin inhibits lipopolysaccharide-induced NF-kappaB activation in human mesangial cells. Nephrol Dial Transplant. 1996;11(6):990-996. 
  77. Sadeghi MM, Collinge M, Pardi R, Bender JR. Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: involvement of an inhibitory G protein. J Immunol. 2000;165(5):2712-2718. https://doi.org/10.4049/jimmunol.165.5.2712
  78. Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A, Plaza JJ, Díaz C, Hernández G, Egido J. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res. 1998;83(5):490-500.  https://doi.org/10.1161/01.res.83.5.490
  79. Ganné F, Vasse M, Beaudeux JL, Peynet J, François A, Mishal Z, Chartier A, Tobelem G, Vannier JP, Soria J, Soria C. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes--a possible protective mechanism against atherothrombosis. Thromb Haemost. 2000;84(4):680-688. 
  80. Takase S, Pascarella L, Lerond L, Bergan JJ, Schmid-Schönbein GW. Venous hypertension, inflammation and valve remodeling. Eur J Vasc Endovasc Surg. 2004;28(5):484-493.  https://doi.org/10.1016/j.ejvs.2004.05.012
  81. Shoab SS, Porter J, Scurr JH, Coleridge-Smith PD. Endothelial activation response to oral micronised flavonoid therapy in patients with chronic venous disease — a prospective study. Eur J Vasc Endovasc Surg. 1999;17(4):313-318.  https://doi.org/10.1053/ejvs.1998.0751

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.